Arecor Therapeutics PLC

As of December 31, 2025, Arecor Therapeutics PLC carries a market capitalization of 3.04B, placing it among publicly traded companies globally. Its enterprise value stands at 2.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Arecor Therapeutics PLC's next confirmed earnings release is scheduled for April 27, 2027.

As of December 31, 2025, Arecor Therapeutics PLC has 37.76M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Arecor Therapeutics PLC maintains a current ratio of 4.78, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Arecor Therapeutics PLC's stock has gained approximately 15.38% over the past 52 weeks. The 50-day moving average sits at 76.17, while the 200-day moving average is 70.43.

As of December 31, 2025, Arecor Therapeutics PLC holds 613.00M in cash and equivalents against 9.80M in total debt, resulting in a net debt position of -300.10M. Total book value stands at 645.40M, with working capital of 609.20M providing operational flexibility.